{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:51Z","timestamp":1789584891893,"version":"build-2803163510"},"reference-count":24,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; We previously presented data of this multicentric, phase II study showing that everolimus plus octreotide long-acting repeatable (LAR) for advanced neuroendocrine neoplasms (NENs), in the first line setting, is an active and safe treatment. We now present updated data at 5 years. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Patients with advanced well-differentiated, previously untreated neuroendocrine tumors of the gastroenteropancreatic tract and of the lung received octreotide LAR 30 mg plus everolimus 10 mg\/day. The primary endpoint was the objective response rate (ORR). We performed an analysis of \u201clong responder\u201d patients and of time to progression (TTP) and overall survival (OS) at 5 years. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Fifty patients were enrolled; the primary tumor site was: pancreas (14 patients), lung (11 patients), ileum (9 patients), jejunum\/duodenum (2 patients), and unknown (14 patients). Seventeen (34%) of these patients have received treatment for more than 2 years. The median exposure to study drugs was 519.5 days (range 48-2,024). Currently 3 patients are still in treatment. The ORR (partial response + complete response) was 18% (95% confidence interval [CI] 7.4-28.6): complete response 1 patient (2%), partial response 8 patients (16%), stable disease 37 patients (74%). The median TTP was 33.6 months (95% CI 18.7-41.2) and the median OS was 61.0 months (95% CI 49.8-not reached). &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In this update of clinical outcome at 5-year follow-up, everolimus plus octreotide has been shown to be active in advanced NENs. The current analysis showed a further prolongation of TTP and a long exposure to the study drug without major side effects in the long term.<\/jats:p>","DOI":"10.1159\/000479587","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T21:01:20Z","timestamp":1501016480000},"page":"307-311","source":"Crossref","is-referenced-by-count":17,"title":["Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update"],"prefix":"10.1159","volume":"106","author":[{"given":"Emilio","family":"Bajetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Catena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Iannacone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Di Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Marte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2012.05.001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-07-0202"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24065"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-011-9290-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2669"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9020"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1835-8"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5754\/hge11212"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.5988"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12122"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7858"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00817-X"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0263"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28726"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3458"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt135"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3923"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/479587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/479587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:46:47Z","timestamp":1745426807000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000479587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,5,29]]},"published-print":{"date-parts":[[2018,6,5]]}},"URL":"https:\/\/doi.org\/10.1159\/000479587","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]}}}